Improve Medical Instruments Co EBIT per Share
The EBIT per Share of Improve Medical Instruments Co (300030.SZ) as of Sep 8, 2026 is -0.09 CNY. In the previous year, EBIT per Share was -0.10 CNY — a change of -12.70% (higher).
Get this data via API
Financial Data API
EBIT per Share
-0.09CNY
YoY
-12.70%
Last updated:
The Improve Medical Instruments Co EBIT per Share history
3 Years
10 Years
25 Years
Max
| YEAR | EBIT per Share | YoY |
|---|---|---|
| -0.09CNY | -12.70% | |
| -0.10CNY | -44.73% | |
| -0.18CNY | -238.03% | |
| 0.13CNY | -65.04% | |
| 0.37CNY | +163.76% | |
| 0.14CNY | -741.18% | |
| -0.02CNY | -112.36% | |
| 0.18CNY | +48.65% | |
| 0.12CNY | -10.63% | |
| 0.13CNY | -17.67% | |
| 0.16CNY | +19.60% | |
| 0.14CNY | +38.97% | |
| 0.10CNY | -11.04% | |
| 0.11CNY | +46.85% | |
| 0.08CNY | -45.90% | |
| 0.14CNY | +33.30% | |
| 0.10CNY | +25.28% | |
| 0.08CNY | -66.46% | |
| 0.25CNY | — |
Improve Medical Instruments Co Stock analysis
Frequently Asked Questions about Improve Medical Instruments Co stock
EBIT per Share of Improve Medical Instruments Co is -0.09 CNY in 2026.
EBIT per Share of Improve Medical Instruments Co changed from -0.10 CNY to -0.09 CNY, representing a -12.70% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of EBIT per Share Improve Medical Instruments Co since 2006 – with annual values, charts, and detailed analysis.
EBIT per Share measures operating profit allocated to each outstanding share.
Income Statement — Improve Medical Instruments Co
All Key Metrics — Improve Medical Instruments Co
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth